Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.

A new interesting article has been published in Gynecol Oncol. 2019 Dec; 155(3):473-482. doi: 10.1016/j.ygyno.2019.10.004. Epub 2019 Nov 6. Research Support, N.I.H., Extramural; Research Support, U.S. Gov’t, Non-P.H.S. and titled:

Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.

Authors of this article are:

Fehniger JE, Berger AA, Juckett L, Elvin J, Levine DA, Zajchowski DA.

A summary of the article is shown below:

OBJECTIVE: We analyzed comprehensive genomic sequencing results from paired ovarian cancer samples to identify changes in mutational events over time.METHODS: DNA from paired FFPE tumor samples from 50 ovarian cancer patients in the Clearity Foundation Data Repository was analyzed for genomic mutations (GM), copy number alterations (CNA), microsatellite status (MS), tumor mutation burden (TMB), and loss of heterozygosity (LOH) by hybrid-capture, next-generation sequencing of up to 315 genes. Genomic profiles were compared between samples from the same patient. Poor quality results excluded 6 pairs from all analyses and 9 from CNA or LOH.RESULTS: Forty-four patients with predominantly advanced stage disease (34, 77%) and serous histology (31, 70%) received a median of 3 intervening treatment regimens (range 1-13). Analysis of 22 primary and recurrent sample pairs and 22 recurrent tumor pairs detected a median of 2 GM (range 0-5) and 1 CNA (range 0-6)/sample. TMB, MS, and LOH results were mostly concordant across paired samples. GM were consistent across most pairs [32/44 (73%) concordant], while CNA concordance was less [18/35 (51%)]. No changes were detected in therapeutically relevant GM, but 23% of patients had GM or CNA in the second sample that affect clinical trial eligibility.CONCLUSIONS: Paired ovarian cancer samples demonstrate stable genomic alterations across time. However, discordance was observed for some genes used as eligibility criteria for molecularly targeted clinical trials. Repeat tumor testing may be useful in cases where eligibility for such trials is deemed important after consideration of testing costs and potential clinical benefit.Copyright © 2019 Elsevier Inc. All rights reserved.

Check out the article’s website on Pubmed for more information:

This article is a good source of information and a good way to become familiar with topics such as: Adult; Aged; Clinical Trials as Topic; DNA Mutational Analysis; DNA, Neoplasm; Female; Gene Dosage; High-Throughput Nucleotide Sequencing; Humans; Loss of Heterozygosity; Microsatellite Instability; Middle Aged; Neoplasm Staging; Ovarian Neoplasms.

NativeFolder: The Only Bacterial Culture Medium for the Expression of Soluble Proteins

Interference Test Kit for Assay Validation

Rheumatoid Factor Interference Blocker

New Antibodies from MOLECULAR DEPOT

New Proteins from MOLECULAR DEPOT

New Chemicals from MOLECULAR DEPOT

Molecular Depot

Your specialty peptide, proteins, antibodies and chemical compounds store.